A Phase 2b Randomized, Single-Blinded Study to Evaluate the Safety and Immunogenicity of 80 microg Recombinant Plague Vaccine (rF1V) With and Without Adjuvant at Two Vaccination Schedules in Healthy Adult Volunteers.
Phase of Trial: Phase II
Latest Information Update: 22 Aug 2012
At a glance
- Drugs Yersinia pestis vaccine (Primary)
- Indications Plague
- Focus Adverse reactions
- 01 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Jun 2012 Planned end date changed from 1 Dec 2012 to 1 Jul 2012 as reported by ClinicalTrials.gov.
- 12 Oct 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.